Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
200 participants
INTERVENTIONAL
2024-03-01
2025-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Between March 2024 and September 2025, 200 patients with concomitant cholelithiasis and choledocholithiasis were randomized to either prophylactic biliary stenting (n=100) or no stenting (n=100) after complete stone clearance documented on occlusion cholangiogram during endoscopic retrograde cholangiopancreatography (ERCP).
The primary outcome was symptomatic choledocholithiasis recurrence within 3 months. Secondary outcomes included biliary complications (cholangitis, cholecystitis, post-ERCP pancreatitis, bleeding), radiation exposure metrics, and cost-effectiveness.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
*Effect of Prophylactic CBD Stenting Versus Non Stenting on Recurrence of CBD Stones in Patients Awaiting Cholecystectomy*
NCT07084493
Immediate vs. Elective Endoscopic Removal of Large CBD Stones in High-Risk Elderly Patients
NCT06948279
Double Stent for Biliary Stones in Cirrhotic Patients
NCT07337291
Failed Retrograde Cholangiopancreatography (ERCP) Stone Extraction: Surgical Interference
NCT05746832
Management of Common Bile Duct (CBD) Stones at Laparoscopic Cholecystectomy
NCT00124033
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Choledocholithiasis frequently coexists with cholelithiasis and is typically managed through a two-stage approach: endoscopic retrograde cholangiopancreatography (ERCP) for stone clearance, followed by laparoscopic cholecystectomy to remove the source of stone formation. The timing and sequencing of these procedures, as well as the role of temporary protective measures during the interval between ERCP and cholecystectomy, have been subjects of clinical debate.
Prophylactic biliary stenting after complete stone clearance has been suggested as a potential protective measure to maintain bile duct patency and prevent recurrent stone migration during the waiting period before cholecystectomy. The theoretical advantages include prevention of stent-related complications such as post-ERCP pancreatitis, maintenance of adequate bile drainage, and reduction in recurrent biliary events. However, the actual clinical benefit of this practice has not been definitively established, and temporary stents themselves carry risks including stent occlusion, migration, and infection.
STUDY OBJECTIVES:
Primary Objective: To determine whether prophylactic biliary stent placement after documented complete choledocholithiasis clearance reduces the recurrence of choledocholithiasis in patients awaiting cholecystectomy.
Secondary Objectives: To compare the incidence of biliary complications (cholecystitis, post-ERCP pancreatitis, cholangitis) between the stenting and no-stenting groups, to assess the need for repeat or emergency ERCP during the follow-up period, to evaluate stent-related complications in the stenting group, and to compare radiation exposure metrics, and cost-effectiveness.
STUDY DESIGN:
This is a prospective, randomized controlled trial with parallel assignment comparing prophylactic biliary stenting versus no stenting in patients with complete choledocholithiasis clearance awaiting cholecystectomy. The study is open-label, with outcome assessors blinded to treatment allocation.
STUDY POPULATION:
The study includes adult patients (age 18-75 years) with concomitant cholelithiasis and choledocholithiasis who have undergone successful ERCP with complete stone clearance documented on occlusion cholangiogram. Patients are excluded if they have incomplete stone clearance, altered anatomy precluding stent placement, active cholangitis, immunocompromised status, or contraindications to cholecystectomy.
RANDOMIZATION AND ALLOCATION:
Participants are randomized 1:1 to either the stenting group or the no-stenting group using a computer-generated randomization sequence with permuted blocks. Randomization is stratified by study site to ensure balanced allocation across participating centers. Allocation concealment is maintained through sealed, opaque envelopes.
INTERVENTIONS:
Stenting Group: Following successful ERCP with complete choledocholithiasis clearance (documented on occlusion cholangiogram), a temporary plastic biliary stent (7-10 French) is placed across the sphincter of Oddi to maintain bile duct patency until cholecystectomy.
No-Stenting Group: Patients undergo ERCP with complete choledocholithiasis clearance without placement of a temporary biliary stent and proceed directly to cholecystectomy.
FOLLOW-UP PROCEDURES:
All participants are scheduled for laparoscopic cholecystectomy within 2-4 weeks of ERCP. Clinical assessments are performed at baseline (ERCP), week 1, pre-cholecystectomy (week 2-4), and at 1 month and 3 months post-ERCP. Imaging studies (ultrasound or CT) are performed at baseline and at the 3-month follow-up to assess for stone recurrence.
OUTCOME MEASURES:
Primary Outcome: Recurrence of choledocholithiasis documented on imaging or endoscopy during the 3-month follow-up period.
Secondary Outcomes: Incidence of biliary complications (cholecystitis, post-ERCP pancreatitis, cholangitis); need for repeat or emergency ERCP; stent-related complications; hospital readmission rates; time to cholecystectomy.
STATISTICAL ANALYSIS:
The primary analysis compares the recurrence rate between the two groups using chi-square test or Fisher's exact test. Secondary outcomes are compared using appropriate statistical tests. Intention-to-treat analysis is performed, including all randomized participants in their assigned groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prophylactic Biliary Stenting Group
Patients randomized to this arm receive endoscopic placement of a temporary plastic biliary stent (7-10 French) in the common bile duct after documented complete choledocholithiasis clearance during ERCP. The stent is left in place to maintain bile duct patency during the waiting period before cholecystectomy.
Temporary Plastic Biliary Stent Placement
Endoscopic placement of a temporary plastic biliary stent (7-10 French gauge) across the sphincter of Oddi after documented complete choledocholithiasis clearance on occlusion cholangiogram during ERCP. The stent maintains bile duct patency and is left in place until cholecystectomy.
Endoscopic Retrograde Cholangiopancreatography with Stone Clearance
Standard endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy and complete choledocholithiasis clearance documented on occlusion cholangiogram. No temporary biliary stent is placed.
No Stenting Group
Patients randomized to this arm undergo ERCP with complete choledocholithiasis clearance without placement of a temporary biliary stent. They proceed to laparoscopic cholecystectomy without the protective stent.
Endoscopic Retrograde Cholangiopancreatography with Stone Clearance
Standard endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy and complete choledocholithiasis clearance documented on occlusion cholangiogram. No temporary biliary stent is placed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Temporary Plastic Biliary Stent Placement
Endoscopic placement of a temporary plastic biliary stent (7-10 French gauge) across the sphincter of Oddi after documented complete choledocholithiasis clearance on occlusion cholangiogram during ERCP. The stent maintains bile duct patency and is left in place until cholecystectomy.
Endoscopic Retrograde Cholangiopancreatography with Stone Clearance
Standard endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy and complete choledocholithiasis clearance documented on occlusion cholangiogram. No temporary biliary stent is placed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of concomitant cholelithiasis and choledocholithiasis
3. Successful ERCP with complete choledocholithiasis clearance documented on occlusion cholangiogram during the index procedure
4. Endoscopic sphincterotomy (EST) performed during ERCP
5. Ability to provide informed consent
6. Scheduled for laparoscopic cholecystectomy within 2-4 weeks of ERCP
7. No contraindications to cholecystectomy
Exclusion Criteria
2. Altered biliary anatomy (e.g., previous bilioenteric anastomosis, Roux-en-Y reconstruction)
3. Active cholangitis or sepsis at the time of ERCP
4. Immunocompromised status (HIV/AIDS, active chemotherapy, chronic corticosteroid use)
5. Coagulopathy or anticoagulation therapy that cannot be safely interrupted
6. Pregnancy or lactation
7. Severe cardiopulmonary disease precluding safe anesthesia
8. Contraindications to cholecystectomy (e.g., unresectable malignancy, severe cirrhosis with portal hypertension)
9. Participation in another clinical trial within the past 30 days
10. Unable or unwilling to comply with follow-up protocol
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Liver Institute, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Liver Institute, Menoufia University, Egypt.
Shibīn al Kawm, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhu J, Li G, Du P, Zhou X, Xiao W, Li Y. Laparoscopic common bile duct exploration versus intraoperative endoscopic retrograde cholangiopancreatography in patients with gallbladder and common bile duct stones: a meta-analysis. Surg Endosc. 2021 Mar;35(3):997-1005. doi: 10.1007/s00464-020-08052-y. Epub 2020 Oct 6.
Chaudhary S. Epidemiology of gall stone diseases among patients attending surgical department of a tertiary care hospital in Nepal. Janaki Med. Coll. J.Med. Sci., 2020; 8(1), 50-55.
Cai H, Sun D, Sun Y, Bai J, Zhao H, Miao Y. Primary closure following laparoscopic common bile duct exploration combined with intraoperative cholangiography and choledochoscopy. World J Surg. 2012 Jan;36(1):164-70. doi: 10.1007/s00268-011-1346-6.
Abd El Wahab AE, Khalil OO. Comparative study between primary common bile duct repair with internal stent insertion versus t-tube drainage after common bile duct exploration. Al-Azhar Intern. Med. J., 2022; 3(1), 107-111.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
035931299
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.